Of note, with aficamten treatment: Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score improved by 7 points (95% CI, 5–10), 58.5% of aficamten‐treated versus 24.3% of placebo‐treated patients had ≥1 New York Heart Association class improvement, Valsalva LVOT‐G decreased by 50 mm Hg (95% CI, 44–57), 49.3% of aficamten‐treated versus 3.6% of placebo‐treated patients achieved Valsalva LVOT‐G<30 mm Hg, NT‐proBNP decreased by 80%, and there was a substantial reduction in time spent eligible for septal reduction therapy (78 fewer days [95% CI, −100 to −56] compared with placebo).12 The gene discussed is NPPB; the disease is cardiomyopathy.